Podcasts about wegovy

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic, from medical breakthroughs to lifestyle impacts.Ozempic, a glucagon-like peptide one receptor agonist, mimics a hormone that curbs appetite, slows stomach emptying, and boosts insulin, leading to significant weight loss. Studies from the University of Texas at Arlington show it helps people shed up to twenty percent of body weight over months by suppressing hunger.Exciting pill option now available. Reuters reports the Food and Drug Administration approved Novo Nordisk's twenty-five milligram oral semaglutide pill, branded Wegovy, for chronic weight management in adults with obesity or overweight plus related conditions. In trials from Healthbanks, daily semaglutide pills led to nearly fourteen percent body weight loss over sixty-four weeks, versus two percent on placebo. AOL notes oral Wegovy users lost thirteen point six percent over fifteen months, cutting sick days in half.Beyond weight, new benefits emerge. University of Colorado Anschutz research highlights GLP-one agonists like Ozempic easing knee osteoarthritis pain and improving function in obese patients, per a Denmark and Canada trial.American Cancer Society explains most loss happens in year one, slowing after, with some regain upon stopping, so long-term use with diet and exercise is key. Older adults often quit early, per New York Times via American Medical Association, due to muscle loss or shortages, regaining weight.Pair with healthy habits for best results, listeners. Consult your doctor.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

  In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: The 10 Best Breakfast Foods for Lean Gains. (2:52) Elon is playing chess. (18:36) A homerun protein snack. (26:07) This new machine has Sal excited. (28:06) If you can be a collector of anything, what would that be? (30:33) When old styles become the new thing again. (37:45) Hack for parents with teenagers who are getting into strength training. (41:00) How much exercise do you need to KEEP the muscle you've already built? (46:38) Body contouring with red-light therapy. (49:38) It's about people, not money. (55:21) #ListenerCoaching call #1 – How to overcome constant muscle fatigue. (57:57) #ListenerCoaching call #2 – How to determine the next fitness focus after making significant progress. (1:07:35) #ListenerCoaching call #3 – Advice regarding daily protein intake without shakes and scaling unilateral exercises while following MAPS Split. (1:17:02) #ListenerCoaching call #4 – Advice and tips you may have for navigating my new endeavor of opening a small boutique personal training studio. (1:28:59) Related Links/Products Mentioned Get Coached by Mind Pump, live! Visit https://www.mplivecaller.com  Visit Crisp Power for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP10 for 20% off. Give your snack game a serious upgrade. Crisp Power Protein Pretzels deliver super crunchy and delicious snacks that are up to 28g of protein, low carb, zero sugar, and high in fiber! ** Visit Joovv for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP to get $50 off your first purchase. 0% financing available! ** MAPS 15 Powerlift 50% half from Dec. 21-27th. Code DECEMBER50 at checkout. Mind Pump Store SpaceX Will IPO in 2026. How Much Is SpaceX Stock Worth? Maintaining Physical Performance: The Minimal Dose of Exercise Needed to Preserve Endurance and Strength Over Time Effects of Red Light LED Therapy on Body Contouring HOME | Stoik Gym Visit Paleovalley for an exclusive offer for Mind Pump listeners! ** Discount is now automatically applied at checkout 15% off your first order! ** Mind Pump #2450: The Smartest Way to Use Protein to Burn Fat & Build Muscle Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Dr. Stephen Cabral (@stephencabral) Instagram Jeremy L. Buendia (@jeremy_buendia) Instagram  

Headlines: – Welcome To Mo News (02:00) – AAA Expecting A Record-Setting Year For Holiday Travel (04:30) – Record-Breaking Warmth Chases Away White Christmas Dreams (06:00) – Justice Department Releases New Batch Of Documents In Epstein Investigation (07:00) – U.S. Economic Growth Surged in Third Quarter of 2025 (14:15) – FDA Approves New Wegovy Weight Loss Pill (16:20) – Supreme Court Refuses to Allow National Guard Deployment in Chicago (18:20) – How to Track Santa Claus This Christmas Eve With NORAD's 2025 Tracker (20:30) – What We're Watching, Reading, Eating (23:30) Thanks To Our Sponsors:  – LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Aura Frames -  $35 off best-selling Carver Mat frames | Promo Code: MONEWS – Monarch - 50% off your first year | Promo Code: MONEWS

In this episode of the Smarter Not Harder Podcast, Cynthia Thurlow joins Dr. Scott Sherr for a wide-ranging and refreshingly honest conversation about fasting, female hormones, GLP-1s, and navigating midlife as a high-performing woman. With clarity and nuance, Cynthia breaks down what works — and what backfires — when it comes to metabolic health for women over 35. Join us as we delve into: • Why intermittent fasting isn't a one-size-fits-all solution • How hormone shifts change the fasting game for women • What GLP-1s like Ozempic and Wegovy really do — and don't do • How to stay metabolically flexible through perimenopause This episode is for you if: • You're a woman over 35 trying to fast smarter, not harder • You're curious about GLP-1s but want balanced, science-based insight • You've hit a metabolic wall and need smarter strategies • You want practical, hormone-informed tools for fat loss and focus You can also find this episode on… YouTube: https://youtu.be/5oVPHVbyUcw Find more from Cynthia Thurlow: Website: https://www.cynthiathurlow.com Instagram: https://www.instagram.com/cynthia_thurlow_ Find more from Smarter Not Harder: Website: https://troscriptions.com/blogs/podcast?utm_source=youtube&utm_medium=video&utm_campaign=snh_podcast_guest_episode_2025_10&utm_content=podcast_asset Instagram: https://www.instagram.com/troscriptions Get 10% Off your purchase of Clinical Metabolomics Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions purchase by using POD10 at https://www.troscriptions.com Get daily content from the hosts of Smarter Not Harder by following @troscriptions on Instagram.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Pharmacist Steve Giroux on FDA approval of the Wegovy pill full 318 Wed, 24 Dec 2025 09:45:00 +0000 MXSahP2UGClnVQe0mcVdz86DrWs0trjT news & politics,news WBEN Extras news & politics,news Pharmacist Steve Giroux on FDA approval of the Wegovy pill Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcasting

Dr. Ashley Bernotas of Kaleida Health Weight Management Center on FDA approval of Wegovy pill full 251 Wed, 24 Dec 2025 09:45:00 +0000 ylB3qvtkWp3O32YPG2FAsScKqLddUd1y news & politics,news WBEN Extras news & politics,news Dr. Ashley Bernotas of Kaleida Health Weight Management Center on FDA approval of Wegovy pill Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False

In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht.  Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

WBEN's Tom Puckett on the FDA's approval of the Wegovy pill full 67 Wed, 24 Dec 2025 08:52:00 +0000 OKOYfHqTMtzYsi5M8m9rC1OBh8MZmTct news & politics,news WBEN Extras news & politics,news WBEN's Tom Puckett on the FDA's approval of the Wegovy pill Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcastin

Wegovy will now be offered in pill form. Dr. Howard Lippes from the Jacobs School of Medicine tells us more about the weight loss drug.

Don Arthur, pharmacist and owner of Brighton Eggert Pharmacy sees lots of positives in weight loss drug Wegovy being made available in pill form.

In a newly released email, a US government investigator says that President Donald Trump flew on Jeffrey Epstein's plane many more times than was previously reported. Also: Ukraine says it's suffering widespread power cuts after another night of deadly Russian air attacks; US regulators approve a pill version of the weight loss drug Wegovy; we hear what it's like to have a baby in Bethlehem; and how can you ensure that you'll keep your New Year's resolutions?The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk Picture Credit: US Department of Justice/PA

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

A strike on another suspected drug trafficking boat in the Pacific is again escalating tensions between US and Venezuela. Five people are dead after a plane crash off the coast of Texas. The FDA has approved a pill version of Wegovy. President Donald Trump made his first public comments on the latest release of the Epstein files. Plus, the Kansas City Chiefs are leaving Kansas City, Missouri. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A surprisingly strong GDP report boosted investors' spirits. Plus: American depositary receipts for Novo Nordisk rise after U.S. regulators approved a pill version of weight-loss drug Wegovy. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: The U.S. bans new China-made drones from DJI and Autel Robotics, sparking outrage among pilots. And U.S. regulators approve the first GLP-1 weight-loss pill, a tablet formulation of Novo Nordisk's Ozempic and Wegovy. Daniel Bach hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla and Jim Cramer led off show with the weight loss drug wars: Shares of Novo Nordisk shares surged after the FDA approved the company's Wegovy pill — making it the first oral GLP-1 cleared by regulators for treatment of obesity. ServiceNow CEO Bill McDermott joined the program to discuss his company's deal to acquire cybersecurity startup Armis for $7.75 billion in cash. Hear what McDermott had to say about this year's slump in shares of ServiceNow and other software stocks. Also in focus: Q3 GDP shows 4.3% growth, the AI trade, countdown to Christmas and new data on holiday spending, Tesla gets a big price target boost on Wall Street, the stock that's getting a lift from President Trump's battleship announcement. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The FDA approving the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk. CNBC speaking with the CEO about expanding access and how the pill will increase the company's competitive edge. Then, former U.K. Treasury Minister Jim O'Neill. His outlook for global markets. And President Trump saying “aggressive housing reform” is coming next year. UBS helps look at possible policy changes and the impact to stocks in the sector. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The latest on severe weather across the country and the impact it's having on the holiday travel rush. Also, the U.S. military announces it has conducted another strike on an alleged drug-smuggling boat. Plus, a homeowner slams into a suspected burglar's car in dramatic video. And, the FDA approves a pill version of the weight-loss injectable drug Wegovy. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The US economy picked up speed over the three months to September, as consumer spending jumped and exports increased but consumer sentiment is low, Rahul Tandon hears from a business about what things are like on the ground. The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. And, an important moment for Indian female cricket players seeing their match fees doubled for domestic games.(Photo: A person shops for products imported from Asia at a market in Los Angeles, California, USA, 07 April 2025. Credit: ALLISON DINNER/EPA-EFE/REX/Shutterstock)

New figures suggest the US economy is powering ahead but questions remain about what that really means for businesses? Leanna Byrne looks at what's behind the data. Also, US regulators have approved the first pill version of the blockbuster weight-loss drug Wegovy. And could North Koreans be working remotely for US companies?

https://www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to today's episode of The Hot Options Report—your essential guide to options trading and stock market analysis as we head into the holiday break. Host Mark Longo breaks down the day's market volatility, concentrating on the top options trades and key stock movements driving the tape before the holiday. In this episode, we dive into the massive trading volumes and unusual activity seen across the leaderboard, including a historic day for Novo Nordisk (NVO) and the continued dominance of Tesla (TSLA) and Nvidia (NVDA). On This Episode, We Discuss: The NVO "Pill" Pop: Novo Nordisk shares surged following the landmark FDA approval of the oral version of Wegovy. We analyze the explosion in call volume and what this fundamental shift means for the GLP-1 "Weight Loss War" heading into 2026. Tesla (TSLA) Sentiment: Tesla remains the undisputed king of the tape as it pushes toward key psychological levels. We break down the massive open interest and the "Santa Rally" positioning ahead of the highly anticipated January delivery report. Nvidia (NVDA) & The China Pivot: With reports circulating about a green light for specific AI chip shipments to China, Nvidia is seeing a massive influx of aggressive call buying. Is the "AI Trade" finding a second wind for the new year? Broad Market Check: Is the market gift-wrapped for a year-end surge? We look at the sentiment reflected in the major index options chains amidst thin holiday liquidity and record highs for the S&P 500. Unusual Activity Spotlight: We track the "Hot Trades" of the day, including surprising volume in names like MicroStrategy (MSTR) and Robinhood (HOOD). Year-End Positioning: A look at why traders are rolling positions and selling premium to capture holiday decay. Tune in for detailed insights into each options trade, the macro drivers behind today's tape, and the vital implications for active traders. Get more options data, charts, and analysis at: TheHotOptionsReport.com

Marley Kayden and Jenny Horne discuss their takeaways for today. They discuss economic data, as well as gold and silver hitting new highs. They also note that the FDA approved a Wegovy weight loss pill. They then highlight that Bitcoin pulled back.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

We hear some quick takes on holiday spending, cash transactions, wrapping paper and white Christmases. Holiday Showdown: Surprise gifts or stick to the list? The Food and Drug Administration has approved a pill version of the weight-loss injectable drug Wegovy. We break down the impact this could have on health in America and the potential side effects of the pill.

Novo Nordisk President & CEO Mike Doustdar discusses the recent US approval of Novo Nordisk's Wegovy weight loss pill, the advantage of being the first to market, the availability of the pill, the company's gameplan, and the timeline of the pill's release. Doustdar spoke with Bloomberg's Katie Greifeld.See omnystudio.com/listener for privacy information.

Once again you are driving the U.S. economy even if you have doubts about the future. We'll start with that story today. This is the Business News Headlines for Tuesday the 23rd day of December, thanks for listening. In other news, consumers are seeing lower gasoline prices and we'll share why. Federal regulators have said yes to a new weight loss pill from Wegovy. You know about that pulled 60 Minutes segment about the prison in El Salvador? Well, it aired on a TV app…anyway and Paramount is not…pleased.  We'll have the story. We will also check the numbers in The Wall Street Report and even though airline prices are higher…it's not hurting holiday travel…yet another tip of the hat the U.S. consumer.  Let's go. Thanks for listening! The award winning Insight on Business the News Hour with Michael Libbie is the only weekday business news podcast in the Midwest. The national, regional and some local business news along with long-form business interviews can be heard Monday - Friday. You can subscribe on  PlayerFM, Podbean, iTunes, Spotify, Stitcher or TuneIn Radio. And you can catch The Business News Hour Week in Review each Sunday Noon Central on News/Talk 1540 KXEL. The Business News Hour is a production of Insight Advertising, Marketing & Communications. You can follow us on Twitter @IoB_NewsHour...and on Threads @Insight_On_Business.

En este cierre de año, Wall Street busca impulso mientras los mercados se preparan para una semana corta por las festividades. Aquí están los temas clave del día:

A young police officer blinded in one eye during the Bondi terror attack has been released from hospital in time for Christmas; US regulators have approved the first daily pill version of the blockbuster weight-loss drug Wegovy; Former Liberal MP and renowned paediatrician Dr. Katie Allen has died at the age of 59; Andrew Mountbatten-Windsor has voluntarily surrendered his shotgun licence following a visit from Metropolitan Police firearms officers; A new study from Keele University suggests that swearing can actually boost physical performance and mental focus. THE END BITS Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Host & Producer: Tahli BlackmanBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

The Stoxx 600 reaches a new intra-day high with investors now anticipating the U.S. GDP print later today. Drug giant Novo Nordisk sees its shares soar as it seeks to gain U.S. approval for the pill-form version of its weight-loss drug Wegovy. President Trump has reiterated previous calls for acquiring Greenland from Denmark for national security reasons as he appoints a new envoy to the Arctic territory. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks eventually traded mixed after initially taking their cue from Wall Street, although volumes and news flow remained subdued as markets wound down for the holiday period.JPY extended its prior session's advances, and USD/JPY eventually dipped under 156.00, whilst the CNH saw notable strength. US President Trump said the US will keep the ships and oil seized near Venezuela.Novo Nordisk (NOVOB DC) said the Wegovy pill is approved in the US as the first oral GLP-1 treatment for weight management.European equity futures are indicative of an uneventful cash open with the Euro Stoxx 50 U/C after cash closed -0.3% on Monday.Looking ahead, highlights include German Import Prices (Nov), Spanish GDP Final (Q3), US Richmond Fed (Dec), Durable Goods (Oct), GDP Advance (Oct), PCE Prices (Q3), Industrial Production, Consumer Confidence, Canadian GDP, BoC Minutes (Dec Meeting), Supply from US. Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Alors que 14 % de Français souffrent d'obésité, un traitement médicamenteux, le Wegovy, est commercialisé depuis le 8 octobre 2024 en France, mais sous conditions strictes : ce médicament amaigrissant ne peut être retiré en pharmacie que sur ordonnance et sans être remboursé, et uniquement par des patients atteints d'obésité morbide et âgés de moins de 65 ans.Le Wegovy appartient à une nouvelle famille de médicaments dite des « analogues du GLP-1 », qui suscite, à l'instar de l'Ozempic, un espoir inédit chez les patients comme au sein du corps médical. Sans graves effets secondaires, les pertes de poids spectaculaires qu'ils engendrent promettent de lutter efficacement contre l'obésité mais provoquent également un certain nombre de dérives.Dans cet épisode de « L'Heure du Monde », Pascale Santi, journaliste au service Santé du Monde, détaille pourquoi ces nouveaux traitements suscitent tant d'attentes face à cette maladie, qui touche actuellement plus d'un milliard de personnes dans le monde.Un épisode de Marion Bothorel. Réalisation : Thomas Zeng. Musiques : Amandine Robillard. Présentation et suivi éditorial : Adèle Ponticelli. Rédaction en chef : Jean-Guillaume Santi.Dans cet épisode : extraits d'interviews d'Etienne, patient participant à l'essai clinique en France, du médecin Olivier Ziegler et du correspondant du Monde à Washington, Arnaud Leparmentier, d'une conférence donnée par Oprah Winfrey le 23 septembre 2023, de deux reportages consacrés à l'Ozempic diffusés sur E ! News le 4 juillet 2023 et sur USA Today le 18 octobre 2022, ainsi qu'une publicité d'Ozempic diffusée en 2023.Un épisode publié le 10 octobre 2024---Pour soutenir "L'Heure du Monde" et notre rédaction, abonnez-vous sur abopodcast.lemonde.fr Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Hoje, ‘No Pé do Ouvido, com Yasmim Restum, você escuta essas e outras notícias: Moraes procurou presidente do BC para tratar da venda do Master. FDA aprova versão em comprimido do Wegovy. Câmara cassa passaportes diplomáticos de Eduardo Bolsonaro e Alexandre Ramagem. Wicked anuncia temporada no Rio após sucesso em São Paulo. Morre Vince Zampella, criador de Call of Duty, aos 55 anos. Nature seleciona pesquisas que devem impactar o mundo em 2026. E Havaianas é acusada de “viés ideológico” por nova campanha.See omnystudio.com/listener for privacy information.

Nokukhanya Mntambo speaks to Dr. Pfunzo Machimana, GP & Family Physician Specialist, about how appetite-suppressing drugs like Ozempic and Wegovy are reshaping weight-loss approaches in South Africa, with growing interest in their role beyond diabetes management and implications for diet and health. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Welcome to Ozempic Weightloss Unlocked, the podcast where we explore the latest news and breakthroughs surrounding one of today's most talked about medications.I'm your host, and today we're diving into what you need to know about Ozempic and its growing role in weight management and health.Let's start with the basics. Ozempic is a medication originally approved by the FDA for managing Type 2 diabetes. But here's where it gets interesting. The medication contains semaglutide, the same active ingredient found in Wegovy, which was specifically approved as an anti-obesity treatment. According to Cleveland Clinic, when Ozempic is prescribed for weight loss, it's considered off-label use, meaning doctors are prescribing it for a purpose beyond its original FDA approval.So how does it actually work? Ozempic belongs to a class of medications called GLP-1 receptor agonists. These drugs mimic a hormone your digestive tract naturally produces. When you take Ozempic, your body produces more of this hormone, which decreases your appetite and makes you feel fuller. But it does more than just suppress hunger. Cleveland Clinic explains that semaglutide changes how your body responds to food and weight loss by affecting the signaling between your gut and brain. This is significant because it treats obesity as a metabolic disease, not simply a behavioral problem.The weight loss results speak for themselves. In a landmark study cited by Cleveland Clinic, people using semaglutide combined with lifestyle changes lost about fifteen percent of their body weight in sixty-eight weeks, averaging thirty-four pounds. Those who didn't take the medication lost only about six pounds on average.But listeners, there's an important reality to understand. These medications aren't quick fixes. According to Cleveland Clinic, people often regain weight once they stop taking the medication. A follow-up study mentioned by Sword Health found that people who stopped semaglutide regained about two-thirds of the weight they lost within a year.Here's another critical point. Research shows that up to thirty-nine percent of weight lost on these medications can come from lean muscle, not just fat. This matters because muscle supports your metabolism. When you lose muscle, your body burns fewer calories, which can lead to weight loss plateaus. The solution isn't eating less. According to Sword Health, the most effective approach is preserving and rebuilding muscle through strength-focused movement.It's also important to know that Ozempic isn't suitable for everyone. Cleveland Clinic warns against obtaining these medications through unverified sources or compounded versions. The safety and effectiveness of compounded versions haven't been formally tested and may act differently in your body than FDA-approved versions.Cost remains a significant barrier. Cleveland Clinic notes that these medications can be expensive due to limited insurance coverage, which is why some listeners might be tempted to seek cheaper alternatives online. But that's where caution is essential.Looking ahead, research is exploring additional benefits beyond weight loss. These medications are now being studied for potential effects on aging and other health conditions.The bottom line for our listeners is this: Ozempic can be a powerful tool for managing obesity when combined with lifestyle changes and professional medical supervision. But it requires a long-term commitment and shouldn't be viewed as a quick solution.Thank you for tuning in to Ozempic Weightloss Unlocked. Please subscribe for more episodes exploring the latest developments in weight management medicine and health innovation.This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Antes de Heleno, STF concedeu prisão domiciliar humanitária para 20 e negou para 17, inclusive Bolsonaro. ‘Chance de êxito no primeiro tiro é baixa', diz professor sobre foguete que explodiu no MA. Avião consegue pousar 'sozinho' nos EUA após sistema de emergência ser acionado. EUA aprovam versão em comprimido do Wegovy.

100 episodes?! Cue the confetti, friends!

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wonder why postpartum weight loss can feel so unpredictable—and what's actually considered normal? It's a question so many new moms have. In this episode, we're breaking down what really happens to weight, metabolism, and overall health after pregnancy, without the pressure or unrealistic expectations.I'm joined by Dani, a family nurse practitioner and one of our obesity experts, who's also training to become a certified lactation counselor. Dani is deeply passionate about supporting postpartum women—especially those who are breastfeeding—a group that's often overlooked when it comes to guidance around weight, nutrition, and recovery.Together, we cover the realities of postpartum weight changes and dive into the topics that matter most, including closing the postpartum support gap, understanding normal weight patterns after pregnancy, the hormonal side of appetite and metabolism, breastfeeding and weight, and how to care for yourself after a baby. We also talk through practical ways to eat well during this season, when to consider weight management medications, what the emerging data says about GLP-1 medications during breastfeeding, and recovery and weight support for moms who aren't breastfeeding.We also explore how hormonal shifts influence hunger and metabolism, safe and realistic approaches to weight support, and practical strategies that help new moms feel supported—not rushed—during this intense and transformative period.Follow the full episode for a deeper, more honest look at postpartum wellness and the support moms truly deserve.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

GLP-1 weight loss drugs like Ozempic and Wegovy are being called a miracle for obesity—but what's really happening inside the body?In this episode of The Whole Body Detox Show, host David DeHaas of Living Waters Wellness Center sits down with renowned nutrition expert Jonny Bowden, PhD, known as The Nutrition Myth Buster, to unpack the science, the benefits, and the hidden risks behind GLP-1 medications.Together, they break down what GLP-1 (glucagon-like peptide-1) really is, why these drugs shut down cravings so effectively, and how they've become so powerful that they've altered the economy of Denmark. More importantly, they reveal the physiological consequences most people aren't warned about—especially the reality that up to 40% of the weight lost on GLP-1 drugs may be muscle, not fat.This conversation explores how GLP-1 drugs impact insulin resistance, metabolism, liver health, nutrient depletion, brain fog, and long-term weight regain, and why losing weight without healing the gut, detoxifying the body, and restoring metabolic balance can leave people weaker, inflamed, and frustrated—even at a lower number on the scale.You'll also hear why hunger suppression creates a “low-calorie trap,” how protein and essential nutrients become critical, and what must be done to protect muscle, energy, and long-term health for those currently using—or considering—GLP-1 medications.This episode does not demonize GLP-1 drugs, but it does expose the Trojan horse effects behind rapid weight loss and explains why real food, gut health, toxin removal, stress management, and whole-body healing are essential for sustainable results.and watch The Four Natural Laws of Healing, or explore the 10-Day Healing Retreat at Living Waters Wellness Center.To learn more about Jonny Bowden, PhD, his research, books, and clinical insights, visit his official website:https://www.jonnybowden.com/If you or someone you love is considering—or already using—GLP-1 weight loss drugs, this episode is essential listening.Learn more about natural, sustainable healing and long-term metabolic restoration by visitingSupport the show Ready for your healing journey?Visit our website: www.LivingWatersCleanse.com Or give us a call at: (208) 378-9911Stem Cell Activation Patches:www.StemCellPatch.netGet your Supplements and Natural Body Products Here:www.livingwaterscleanse.com/supplementsQI-Shield EMF Devices:Protect your whole home or office with a touric shield from EMF's. 1. QI Shield Covers 16'x16' 2. QI Home Covers 50' x 50' 3. QI Max Covers 250'x250'Click on link and enter Livingwaters in discount code section during checkout Magnesium Soaks:Follow us on our socials: Living Waters Wellness CenterBitChute: www.bitchute.com/livingwaterswellnessRumble: www.rumble.com/l...

GLP-1 drugs have become one of the most important developments in the pharmaceutical industry. With products like Ozempic, Wegovy, and Mounjaro in high demand, competition between drug makers is growing quickly. In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 inhibitors — the drugs behind today's weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. Their discussion also looks at a major recent development: Pfizer's acquisition of biopharma startup Metsera, and why this deal could significantly change the market. Skip and Dez's conversation gives listeners a clear and practical introduction to competition and strategy in the pharmaceutical industry — while helping you improve your Business English. In this episode, you will learn: What GLP-1 drugs are and what they are used for. The main differences between Ozempic, Wegovy, Mounjaro, and Zepbound. Why Eli Lilly is gaining market share, especially in North America. How Pfizer's acquisition could affect future weight-loss treatments. Do you like what you hear? Become a D2B Member today for to access to our -- NEW!!!-- interactive audio scripts, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes. Visit d2benglish.com/membership for more information. Follow Down to Business English on Apple podcasts, rate the show, and leave a comment. Contact Skip, Dez, and Samantha at downtobusinessenglish@gmail.com Follow Skip & Dez Skip Montreux on Linkedin Skip Montreux on Instagram Skip Montreux on Twitter Skip Montreux on Facebook Dez Morgan on Twitter RSS Feed

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

What happens when a medication designed to help you lose weight also changes what brings you pleasure?In this solo episode, I'm doing a deep dive into what nobody's discussing about GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and what they do to your sex life.These medications have been absolutely transformational for metabolic disease, obesity, and cardiovascular health. But they don't just work on your gut and pancreas they work centrally in your brain, in your reward pathways, in your pleasure centers.I'm sharing stories from my practice: the glamorous patient who suddenly didn't want to shop anymore. The wine connoisseur who lost interest in drinking. The foodies who can't stand restaurants. And yes, the patients whose sexual desire completely disappeared because their brain stopped experiencing reward the same way.Highlights:Why GLP-1 medications are actually anti-inflammatory powerhouses (and what that means for PCOS, endometriosis, even PGAD).How these drugs modulate dopamine and serotonin the same pathways that control sexual desire.Why improving body image doesn't always improve sexual function (the biopsychosocial model).The emerging science on GLP-1s reducing alcohol cravings, substance use, and compulsive behaviors.What SHBG changes mean for your free testosterone and libido.Why your brain doesn't compartmentalize pleasure food, shopping, alcohol, and sex all use the same reward circuits.The informed consent conversation every doctor should be having (but isn't).If you're on a GLP-1 medication or considering starting one, ask your doctor about how it might affect what brings you pleasure including sex. With great power comes great responsibility, and sexual health is health. Period.Get in Touch with Me:WebsiteInstagramYoutubeSubstackMentioned in this episode:GSM CollectiveThe GSM Collective - Chicago Boutique concierge gynecology practice Led by Dr. Sameena Rahman, specialist in sexual medicine & menopause Unrushed appointments in a beautiful, private setting Personalized care for women's health, hormones, and pelvic floor issues Multiple membership options available Ready for personalized women's healthcare? Visit our Chicago office today. GSM Collective

The Menopause Solution with Dr. Lauren Fitzgerald What was the black box warning? Why was it there? Why is it now gone? (2:09) An interesting symptom of perimenopause. (8:12) Progesterone will change your life! (9:52) The importance of monitoring your thyroid levels and the 10 most common low-thyroid symptoms. (14:20) Testosterone for women. (22:57) Her main issue with primary care doctors. (27:14) The role of peptides in her practice. (30:01) The buy-in. (30:47) Ranking the various applications of testosterone. (33:39) The BIG myths surrounding HRT. (36:03) It's not a business, it's a mission. (40:26) GLP-1s: Incredible tools when used appropriately. (41:40) Normal isn't OPTIMAL. (45:27) The missing element for MOST people. (55:51) Related Links/Products Mentioned Visit Pre-Alcohol by ZBiotics for an exclusive offer for Mind Pump listeners! ** Promo code MINDPUMP25 for 15% off first-time purchasers on either one-time purchases (3, 6, 12-packs) or subscriptions (6, 12-pack) ** MAPS 15 FORTY PLUS 50% half from Dec. 14-20th. Code DECEMBER50 at checkout. Mind Pump Store FDA to Remove 'Black Box' Warnings From Menopause Hormone Therapy. Here's Why. The WHI Study: How Misinterpretation of Hormone Therapy Data Hurt Women's Health Welcome to the 'menodivorce'. Why women aren't sweating marriage in a sea of hot flashes Estrogen Matters: Why Taking Hormones in Menopause Can Improve and Lengthen Women's Lives -- Without Raising the Risk of Breast Cancer Mind Pump #2502: Hormone Therapy for Aesthetics With Dr. Lauren Fitzgerald Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Muscle Mommy Movement Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned LAUREN FITZ, M.D. (@drlaurenfitz) Instagram Website Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

SpaceX IPO coming – huge increase in valuation over past 3 months Happy Hanukah – Eight Crazy Nights Now Kevin AND Kevin PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Last Chance for CTP Cup 2025 participants - Happy Hanukah - Eight Crazy Nights - Sad News - Rob Reiner - Fed decision is out.... - Overdue eco reports coming this week Markets - Oracle still problematic - SpaceX IPO coming - huge increase in valuation over past 3 months - Another Bankruptcy - cleaning up is not good business - Oh my - Now Kevin AND Kevin - Weight loss game continues - One thing saved for last - a doozie... Tesla -  - All time High - Prospect of Robotaxi - Even though sales hitting multi-year lows Wall Street Never Sleeps? - Nasdaq files to extend trading to 23 hours on weekdays - Banks concerned about investor protections, costs, liquidity, volatility risks of nonstop trading - Proponents argue round-the-clock trading benefits global investors - That may create some additional volatility potential SpaceX - SpaceX aims for a potential $1.5 trillion market cap with an Initial Public Offering in 2026, which could become the largest IPO in history - July 2025 tender valuation was $400B - Dec 14th (4 months later) $800B - Starlink is the primary money winner of this deal - Tesla shares climbing even with nothing behind it - seemingly in sympathy for this IPO ---- TESLA does not have ownership of SpaceX - OH - this could be the reason....U.S. deliveries dropped significantly in November—the lowest since early 2022—but this weakness has been overshadowed by the enthusiasm for autonomy. Rob Reiner - A son of legendary Hollywood director Rob Reiner and his wife, producer Michele Singer Reiner, Nick Reiner, is being held on suspicion of murder following their deaths, according to Los Angeles Police Department Chief Jim McDonnell. He's being held on $4 million bail. - Citing law enforcement sources and family friends, ABC News reported on Monday that Nick Reiner had recently returned to live at his parents' South Chadbourne Avenue home. The move was described as a temporary arrangement intended to help him stabilize. - Not going to discuss the Truth Social post about this tragedy HEADLINE ALERT - "Copper could hit ‘stratospheric new highs' as hoarding of the metal in U.S. continues" - Copper has gone from 5.77 to 5.30 (July to today) - 6 Tops at this price since 2011 - Not seeing this as per the headline - seems like a Hunt Brothers special from the 1980s - CORNERING THE MARKET ---1980 - Silver went from $11 to $50 then crashed, bankrupting the Hunt Bros - after COMEX changed rules forcing them to cover positions Bankruptcy - After 35 years, the maker of the Roomba robot vacuum filed for bankruptcy protection late Sunday night. Following warnings issued earlier this year that it was fast running out of options, iRobot says it is entering Chapter 11 protection and will be acquired by its contract manufacturer, China-based Picea Robotics. - The company says it will continue to operate “with no anticipated disruption to its app functionality, customer programs, global partners, supply chain relationships, or ongoing product support.” - Remember that Amazon  - The Amazon buyout of iRobot, maker of Roomba, was announced in 2022 for $1.7 billion but ultimately failed in January 2024 due to significant regulatory pushback, primarily from the EU, over anti-competitive concerns. -- Amazon walked away with a $94 million termination fee Fed Pick - President Donald Trump said Friday that Kevin Warsh has moved to the top of his list as the next Federal Reserve chair, though Kevin Hassett also remains in contention, according to the Wall Street Journal. - Interesting that this comes days after Hassett said that we would not let outside suggestions influence his voting - ---In addition to putting heavier weight on Warsh getting the job, Trump repeated an assertion he has made in the past that the Fed chair ought to consult the president about interest rate decisions. - Also of interest, prediction markets had Hassett at 95% probability - now it moved to 50% - big payday for people in the know. Housing Prices - Average home price is DOWN on  year-over-year basis - First time on national level since 2024 - Active listings in November were nearly 13% higher than November 2024, but new listings were just 1.7% higher --- Houses are on market longer - - Prices in Austin, Texas, are down 10% from last year; in Denver, they're down 5%, according to Parcl Labs. Tampa, Florida, and Houston both saw prices fall 4%, and Atlanta and Phoenix saw price decreases of 3%. More Hosing Related -  Zillow shares plunged more than 9% on Monday on worries that the online real estate platform could have a big new competitor: Google Search. - Google appears to be running tests on putting real estate sale listings into its search results. Overdue Eco  - Black Hole - The U.S. Bureau of Labor Statistics on Tuesday releases its long-awaited combined employment reports for October and November, but a number of key details will be missing after the government shutdown prevented data collection, including October's unemployment rate, resulting in the first-ever gap in that critical data series since inception in 1948. - NICE JOB GANG! - Some of the data will be estimated. - It said it would not publish the headline CPI number or the so-called core CPI, which strips out the volatile food and energy components, for October. "BLS cannot provide specific guidance to data users for navigating the missing October observations," the agency said. Some Updates - Some info coming in are estimates - some delayed - Unemployment at 4.6% - Latest report shows +64,000 added - ISM Manufacturing and Non-manufacturing - both slowed over the last month The Fed - Meanwhile the Fed cuts rates.... - A Federal Reserve split over where its priorities should lie cut its key interest rate Wednesday in a 9-3 vote, but signaled a tougher road ahead for further reductions. - The FOMC's “dot plot” indicated just one more reduction in 2026 and another in 2027, amid considerable disagreement from members about where rates should head. - In addition to the rate decision, the Fed also announced it will resume buying Treasury securities. The central bank will start by buying $40 billion in Treasury bills, beginning Friday. - Markets were all over the place on this as it was a little confusing at first - then it seemed that everyone loved (for one day) - Why is the Fed moving up Treasury purchases to "immediately" from a few months from now? - AND - dissension ! A larger group  that usual of regional Fed bank presidents signaled they opposed the cut, and six policymakers said the benchmark federal funds rate should end 2025 in a range of 3.75% to 4%, suggesting they opposed the move. - Long bonds have not moved at all on this news. Costco Earnings - Costco beat Wall Street's fiscal first-quarter sales and revenue expectations. - Sales rose 8.2% and digital sales jumped 20.5% compared with the year-ago quarter. - Costco surpassed Wall Street's quarterly expectations and posted year-over-year sales growth of 8.2% as the retailer attracted more digital sales and opened new locations. - Earnings per share: $4.50 vs. $4.27 expected - Revenue: $67.31 billion vs. $67.14 billion expected - Costco does not provide year ahead guidance - Shares down from a recent high of $855 Costco Fun Facts - About 4.5 million pies were sold in the three days before Thanksgiving, which is equivalent to roughly 7,000 pies per warehouse. -  These were bakery pies (e.g., pumpkin, apple), - Costco had more than $250 million in non-food online orders on Black Friday, a record for Costco's U.S. e-commerce business. - Approximately 358,000 whole pizzas were served at Costco's U.S. food courts, a 31% jump from last year. (500 pizza's per store) Fat No More - Retatrutide - Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. - In a 48-week Phase 2 study, participants on the highest dose lost an average of 24% of their body weight. - Recent Phase 3 results showed patients on the highest dose lost an average of 28.7% of their body weight after 68 weeks. - The trials also showed improvements in related health conditions, including knee osteoarthritis pain, blood pressure, and liver fat - This triple action is what makes retatrutide potentially more effective for weight loss than existing medications like Zepbound (tirzepatide), which targets two receptors, or Wegovy (semaglutide), which targets only one. Paypal - PayPal Holdings Inc. applied to become a bank in the US, looking to take advantage of the Trump administration's openness to financial-technology companies entering the banking system. - The payments-focused firm submitted applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions to form a Utah-chartered industrial loan company, PayPal said in a statement Monday. - If approved, PayPal Bank would help the firm bolster its small-business lending capabilities, according to the statement, which said the company has provided access to more than $30 billion in loans and capital since 2013. Ford - Management Confused - Instead of planning to make enough electric vehicles to account for 40 percent of global sales by 2030—as it pledged just four years ago—Ford says it will focus on a broader range of hybrids, extended-range electrics, and battery-electric models, which executives now say will account for 50 percent of sales by the end of the decade. - The automaker will make hybrid versions of almost every vehicle in its lineup, the company says. - All in on EVS cost them -  Ford expects to record about $19.5 billion in special items, mostly during the fourth quarter. ---- The charges are related to a restructuring of its business priorities and a pullback in its all-electric vehicle investments. Australia - Australia has implemented a groundbreaking ban preventing children under 16 from accessing major social media platforms like TikTok, Instagram, and Facebook, effective December 2025, to protect them from harm, with significant fines for companies failing to enforce it, though messaging apps and gaming platforms are currently exempt. - Reddit is suing - Facebook, Instagram, Snapchat, Threads, TikTok, X (Twitter), YouTube, Reddit, Kick, and Twitch are all banned for kids under 16. - Thoughts on this? Saved For Last - Of all the eye-popping numbers that Oracle Corp. published last week on the costs of its artificial-intelligence data center buildout, the most striking didn't appear until the day after its earnings press release and analyst call. - The more comprehensive 10-Q earnings report that appeared on Thursday detailed $248 billion of lease-payment commitments, “substantially all” related to data centers and cloud capacity arrangements, the business-software firm said. These are due to commence between now and its 2028 financial year but they're not yet included on its balance sheet. - That's almost $150 billion more than was disclosed in the footnotes of September's earnings update. Love the Show? Then how about a Donation? The Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.

What No One Tells You About Life After GLP-1 Meds GLP-1 medications like Ozempic, Wegovy, and Mounjaro have changed the game for weight loss—but what happens when the prescription ends and you need a plan? This week, I'm joined by Dr. Jim Hill, leading obesity researcher and architect of the National Weight Control Registry, to uncover what really happens after GLP-1s—and how to maintain your results without spiraling into regain. We'll explore the three types of weight regain, what makes maintenance so different from weight loss, and why your body is capable of mimicking GLP-1 effects naturally—if you know how to support it. Whether you're on these meds now, thinking of stopping, or just want to protect your progress, this is a must-listen.

Holiday urgency is real, whether you are trying to squeeze into your jeans or squeeze in those last few deals, and on this Bathroom Break Daniel Murray pulls Jay Schwedelson into a fast, funny riff on how to make that urgency actually pay off. They get into a wild "ate through the shot" Wegovy story, then flip it into simple, budget friendly tactics that push people to buy or opt in without feeling gimmicky. From DTC countdown discounts to B2B content that literally expires, you get plug and play ideas you can steal before the year is over.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(01:08) Jay admits he tried Wegovy expecting magic, then laughs about how he "ate through the shot" and ended up just eating less instead.(02:30) Daniel calls out how much money Jay wasted on the shot before pivoting into the real topic of using urgency to close year end revenue and email goals.(03:22) Daniel breaks down Set Active's "Set Miss" promo and why shrinking discount windows instantly force shoppers to make a decision.(05:26) Jay shares a dead simple B2B play where you put a countdown on how long a guide is available, then actually remove it from your resources page.(07:11) They brainstorm a "12 days of content" idea where every day a new curated asset drops and then expires to rapidly grow your email list.(08:23) The chat drifts into holiday party avoidance, sweatpants vs real pants, and Jay getting officially banned from wearing his hat backwards at 50.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/